ENANTA PHARMACEUTICALS INC ENTA
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
4/9
Piotroski F — financial health
-2.79
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $65.3M | -$81.9M | — | -$32.2M | $64.7M |
| 2024 | $67.6M | -$116.0M | — | -$96.7M | $128.8M |
| 2023 | $79.2M | -$133.8M | — | -$112.2M | $216.7M |
| 2022 | $86.2M | -$121.8M | — | -$86.9M | $321.3M |
| 2021 | $97.1M | -$79.0M | — | -$70.7M | $399.4M |
| 2020 | $122.5M | -$36.2M | — | $5.6M | $455.6M |
Why these scores methodology →
Piotroski F-score: 4/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -2.79 (distress)
- Working capital / assets 0.555
- Retained earnings / assets -1.442
- EBIT / assets -0.304
- Equity / liabilities 0.3
Source: SEC EDGAR filings · CIK 0001177648 · as of 2025-09-30. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.